Podium Presentations S19 12 weeks post-BTM while Group C were sacrificed 12 [n = 6], 24 [n = 6] and 52 [n = 6] weeks post-BTM. At necropsy, both medial compartments of BTM joints were scored by 2 blinded observers for AC lesions and osteophytes (OP) using a 0−4 scale. Synovial tissue and a 5 mm wide coronal osteochondral slice were removed from the mid-line of the femur and tibia and processed for histochemical and histomorphometric analyses using published methods. Intact patellae were used for topographical biomechanical AC indentation studies. Results: Gross morphological scores 12 wks post BTM showed a dosedependent effect of MPC on AC integrity and OP formation; 100 mil MPC emerging as the most effective chondroprotective dose relative to HA alone. Total AC score ratios (HA+MPC)/(HA) showed 100>150>25 = 10 while OP ratios were 100>25>10>150 mil MPC. Statistically significant (SS) lower scores were observed for total femoral & tibial AC (p = 0.019) and total AC and OP (p = 0.009) for Group C MPC joints compared HA alone. Histomorphometric analysis of Group C MPC+HA tibial plateaus revealed that AC were thicker than the corresponding HA-AC in the middle (p = 0.057) and outer regions (p = 0.028); for all regions (p = 0.01). The mean phase lag for the patellae AC of Group C MPC injected joints was significantly lower than the contralateral patella AC (p = 0.002). Mean modified Mankin scores for AC sections from Group C MPC+HA joints were less than corresponding HA sections but were not SS. There was no evidence of synovial histopathology modulation. The chondroprotective effects observed for the 100 mil MPC injected joints diminished with time; the positive effects noted at 12 and 24 weeks BTM being lost by 52 weeks. Conclusions: This is the first report, as far as we are aware, of a beneficial therapeutic effect of allogenic Stro-3+ MPC on cartilage integrity in a model of early OA. MPC/MSC are known to release growth factors and cytokines and also suppress the production of TNF-alpha by other cells, while up-regulating anti-inflammatory cytokines (eg. Il-4, Il-10). These paracrine activities of MPC could stimulate chondrocyte biosynthesis of new matrix but also attenuate local production and activity of catabolic mediators. The finding in this study that 100 million MPC were chondroprotective was consistent with such a mechanism of action. Purpose: Lubricin is a synovial glycoprotein that supplies a frictionresistant, anti-adhesive coating to the surfaces of articular cartilage, thereby protecting against arthritis-associated tissue wear and degradation. We generated and characterized a novel lubricin protein construct, "LUB:1", and evaluated its therapeutic efficacy following intraarticular delivery in a well-characterized rat model of osteoarthritis (OA). Methods: An optimized lubricin protein construct (designated "LUB:1"), containing a truncated mucin-like domain, was expressed in stably transfected CHO cells. Purified LUB:1 was biochemically characterized and analyzed ex vivo for its ability to bind to and lubricate cartilage surfaces, and to prevent cellular adhesion. For in vivo studies (IACUC approved), unilateral OA was induced in the knees of male Lewis rats (n = 20 animals/treatment group) by transection of the medial collateral ligament and meniscus ('meniscal tear'-induced OA). At one week post-surgery, LUB:1 (20 mg/40 ml), or phosphate-buffered saline (PBS) vehicle (40 ml) was administered by intraarticular injection, with dosing either once per week or 3 times per week over a subsequent four week period. At the end of the studies, tissue sections of each knee joint were analyzed microscopically and assessed for multiple pathological parameters of OA. Results: LUB:1 maintains functional N-terminal domains which facilitate mutimerization, is appropriately substituted with lubricating O-linked oligosaccharides, and possesses integral C-terminal domains enabling binding and localization to cartilage surfaces. LUB:1 is an effective cartilage boundary lubricant and inhibitor of cellular adhesion. Local delivery of LUB:1 was therapeutically effective in preventing cartilage degradation during the progression of OA. Knee joints from rats treated with LUB:1 developed significantly less severe cartilage damage than PBS (vehicle)-treated animals, and displayed significantly reduced cartilage degeneration scores (general pathology), total joint scores and cartilage lesion and degeneration width measurements. Strikingly, the width of severe cartilage lesions, reflecting areas of tibial cartilage damage in which tissue matrix loss extends through 50% or more of the cartilage depth, was decreased by 83% in response to LUB:1 administered 3 times per week. Inhibition of loss of viable matrix further indicated beneficial effects of LUB:1 on overall cartilage tissue preservation (chondrocytes, proteoglycan and collagen). Subchondral bone scores did not differ between treatment groups, indicating that joint loading was comparable in all animals. Evidence of fibroplasia was not observed in response to LUB:1 treatment, thus supporting a favorable tolerability profile for recombinant lubricin in the treatment of joint diseases. Conclusions: Intraarticular supplementation of rat knee joints with LUB:1 resulted in significant disease-modifying, chondroprotective effects during the progression of osteoarthritis, by markedly reducing cartilage degeneration and structural damage. The use of recombinant lubricin molecules is thus indicated for novel biotherapeutic approaches in the treatment of cartilage pathologies associated with osteoarthritis. Purpose: Orchestrated movement of cells in a particular direction to a specific location is a central process for tissue development, maintenance and repair. The understanding of cell migration and chemotactic mechanisms may lead to the novel therapeutic strategies for tissue repair or regeneration. The aim of this study was to identify cytokines and growth factors that are able to induce migration of human articular chondrocytes and mesenchymal stem cells (MSCs). Methods: Isolated normal human articular chondrocytes and human bone marrow-derived MSCs were used. Chemotaxis assays were performed in modified Boyden chambers using 48-well microchemotaxis chamber plates with polycarbonate PVP free membranes with 8-mm pores. Growth factors were diluted to appropriate concentrations in DMEM/F12 supplemented with 0.1% FBS, and placed in the lower chamber. Approximately 2×10 4 cells were allowed to attach to the top wells of the insert. After 24 h incubation, the migrated cells on the lower side of the inserts were fixed, stained and counted for 4 random fields per well under light microscope at 100× magnification. The results are expressed as total number of migrated cells. Results: Progressive chemotactic effects were observed with increasing FBS concentrations between 0−20%. Among a series of growth factors and cytokines tested only PDGF induced a significant increase in cell migration. TGFb, VEGF, IGF-1, Il-8, bFGF, BMP-2, BMP-4 and BMP-7 had no significant effects on chondrocytes. The PDGF isoforms AB and BB were more potent than AA. In human articular chondrocytes there was a significant aging related decline in the ability of cells to migrate in response to serum and PDGF. MSCs significantly responded to FBS and several factors, including FBS, PDGF, VEGF, IGF-1, Conclusions: This study demonstrated that directed cell migration is inducible in human articular chondrocytes and MSC and identified PDGF as the most potent chemotactic factor. The present results also demonstrate an aging-related reduction in the migratory response of human articular chondrocytes. The ability of human articular chondrocytes to migrate in response to serum and PDGF, supports the potential of augmenting this cellular response in cartilage repair and tissue engineering.
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A14 CHEMOTAXIS OF HUMAN ARTICULAR CHONDROCYTES

A15 SUCCESSFUL INTEGRATIVE CARTILAGE REPAIR IN VITRO
CAN BE ACHIEVED BY INHIBITING CHONDROCYTE DEATH AT THE WOUND EDGE
S.J. Gilbert, S.K. Singhrao, I.K. Khan, V.C. Duance, C. Archer. Cardiff University, Cardiff, UNITED KINGDOM Purpose: Experimental wounding of articular cartilage results in necrotic and apoptotic chondrocyte death at the lesion edge. Viable cells at the wound edge are critical for producing a repair tissue capable of integrating with the native cartilage. The aims of this study were to investigate whether inhibiting the cell death at the wound edge results in enhanced integrative cartilage repair. Methods: Full depth, bovine articular cartilage discs (6 mm) were harvested from the metacarpophalangeal joint of 7-day old calves. Cartilage discs were pre-incubated in media containing inhibitors of necrosis (Necrostatin-1; 30 mM) or apoptosis (Z-VAD-FMK, 20 mM) prior to cutting a central 3 mm inner core. This core was left in situ to create disc/ring composites in order to study cartilage-cartilage integration. Cartilage was cultured for 2-weeks with the above inhibitors and analysed for necrotic
